GlassScriptPhysician profile
Stanlee S Lu
NPI 1205161700
$6,795.04
in general payments reported to CMS, 2019-2025
59 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $73.88 · 2021: $512 · 2022: $765 · 2023: $1,399 · 2024: $1,529 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,521.67 |
| Education | $174.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.73 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $503.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $474.17 | 2019-2024 | Opdivo, Opdualag, Augtyro |
| Pfizer INC. | $402.98 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $363.80 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Celgene Corporation | $353.66 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Janssen Biotech, INC. | $344.10 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Pharmacyclics LLC, An Abbvie Company | $308.17 | 2021-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $288.90 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $223.56 | 2019-2025 | |
| Genentech USA, INC. | $222.83 | 2019-2025 | Lunsumio, Polivy, Itovebi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.44 | 2021-2023 | Gilotrif |
| Astellas Pharma US INC | $184.81 | 2019-2024 | Xospata |
| Gilead Sciences, INC. | $180.19 | 2021-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $173.40 | 2019-2024 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $159.04 | 2021-2025 | Braftovi, Lorbrena, Xalkori |
| Regeneron Healthcare Solutions, INC. | $150.76 | 2024-2025 | Libtayo |
| Incyte Corporation | $137.03 | 2022-2025 | Jakafi, Niktimvo, Monjuvi |
| Emd Serono, INC. | $121.55 | 2019-2025 | Tepmetko |
| Sobi, INC | $92.92 | 2022-2023 | |
| Seagen INC. | $77.51 | 2021-2023 | Adcetris |
| Stemline Therapeutics INC. | $75.37 | 2024-2025 | Orserdu |
| Daiichi Sankyo INC. | $72.05 | 2019-2021 | |
| Taiho Oncology, INC. | $66.05 | 2022-2025 | |
| Eisai INC. | $61.07 | 2022-2025 | |
| Morphosys, US INC. | $59.81 | 2023-2024 | Monjuvi |
| Merck Sharp & Dohme LLC | $55.47 | 2023-2025 | Keytruda, Lynparza, Dificid |
| Mirati Therapeutics, INC. | $54.59 | 2023-2024 | Krazati |
| Tersera Therapeutics LLC | $48.29 | 2022-2025 | Quzyttir |
| Coherus Oncology, INC. | $48.19 | 2023-2024 | |
| Beigene USA, INC. | $47.92 | 2025 | Tevimbra, Brukinsa |
| Iovance Biotherapeutics, INC. | $46.65 | 2025 | Amtagvi |
| Epizyme, INC. | $39.82 | 2022-2023 | Tazverik |
| Adc Therapeutics America, INC. | $39.24 | 2024-2025 | |
| Octapharma USA, INC. | $37.35 | 2019 | |
| Fresenius Kabi USA, LLC | $37.29 | 2023-2024 | Stimufend |
| Acrotech Biopharma INC. | $35.31 | 2023-2024 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $33.21 | 2023-2024 | Fotivda |
| Dendreon Pharmaceuticals LLC | $32.37 | 2022-2025 | Provenge |
| Takeda Pharmaceuticals U.S.A., INC. | $31.40 | 2024 | Alunbrig |
| Ipsen Biopharmaceuticals, INC | $30.30 | 2024 | Onivyde |
| Clovis Oncology, INC. | $27.45 | 2019 | |
| Beone Medicines USA, INC. | $25.37 | 2025 | Brukinsa |
| Recordati_rare_diseases_inc. | $24.69 | 2025 | Enjaymo |
| Cti Biopharma Corp. | $24.19 | 2023 | Vonjo |
| Accord Healthcare, INC. | $24.19 | 2024 | |
| Ge Healthcare | $23.88 | 2021 | |
| Azurity Pharmaceuticals, INC. | $23.08 | 2025 | Danziten |
| Pharmacosmos Therapeutics INC. | $21.33 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.30 | 2024 | Onpattro |
| Blueprint Medicines Corporation | $19.64 | 2023 | Ayvakit |
| Amgen INC. | $19.39 | 2019 | |
| Adaptive Biotechnologies Corporation | $17.47 | 2024 | Clonoseq |
| Sumitomo Pharma America, INC. | $14.88 | 2024 | Orgovyx |
| Lilly USA, LLC | $13.79 | 2025 | Verzenio, Jaypirca |
| Echosens North America, INC. | $13.22 | 2024 | Fibroscan |
| Verastem, INC. | $11.72 | 2019 | |
| Dova Pharmaceuticals | $11.37 | 2019 | |
| Fortovia Therapeutics, INC. | $7.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanlee Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.